Introduction There are positive aspects regarding the prescribing of fixed dose combinations
(FDCs) versus prescribing the medicines separately. However, these have to be balanced …

The global public health community has set ambitious treatment targets to end the HIV/AIDS
pandemic. With the notable absence of a cure, the goal of HIV treatment is to achieve …

Background Two drugs under consideration for inclusion in antiretroviral therapy (ART)
regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and …

Background Many countries are now replacing non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based first-line antiretroviral therapy (ART) with a regimen containing …

Background The integrase inhibitor dolutegravir could have a major role in future
antiretroviral therapy (ART) regimens in sub-Saharan Africa because of its high potency and …

A new first-line antiretroviral therapy (ART) regimen containing dolutegravir is being rolled
out in low-income and middle-income countries (LMICs). In studies from predominantly high …

Background Increased access to antiretroviral therapy (ART) has resulted in rising levels of
pretreatment human immunodeficiency virus drug resistance (PDR). This is the first …

In 2014, the Joint United Nations Programme on HIV and AIDS established global targets
such that 90% of people with HIV will be diagnosed, 90% of those diagnosed will be on …

After 15 years of global scale-up of antiretroviral therapy (ART), rising prevalence of HIV
drug resistance in many low-income and middle-income countries (LMICs) poses a growing …

Abstract Background South Africa has the largest public antiretroviral therapy (ART)
programme in the world. We assessed temporal trends in pretreatment HIV-1 drug …